MA-ALLURION-TECHNOLOGIES
Allurion Technologies announced today two major milestones with the launch of the transformed Allurion Weight Loss Program and new worldwide brand for the company and its program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005001/en/
Allurion began commercial sales of its flagship Elipse® Gastric Balloon in 2016. Over the past five years, the company has treated over 50,000 patients across 40 countries. In that time, the company’s weight loss solution has evolved from a single device to a comprehensive program that combines medical, digital, and nutritional approaches to jumpstart weight loss and form lifelong healthy habits.
The new Allurion Program unveiled today features:
- The Allurion® Balloon, rebranded to reflect its synergistic role with other features in the program
- The Allurion® Virtual Care Suite, enabling end-to-end patient management through the Allurion Health Tracker, Connected Scale, and App
- Allurion Insights, offering providers real-time patient analytics and telehealth features
The Allurion Balloon is the world’s first and only procedureless™ medical device for weight loss that leads to 10-15% total body weight loss in approximately 16 weeks. Over 50,000 patients have been treated with the Allurion Balloon, and its re-branding not only reflects its role within the Allurion Program but also device improvements that have been made to optimize the patient and provider experience.
The Allurion Balloon works hand-in-hand with the Allurion® Virtual Care Suite. The Virtual Care Suite includes tools for the patient and the provider to have a 360-degree weight loss experience designed to deliver lifelong results. The patient receives the Allurion Health Tracker, Connected Scale, and App to track, monitor and support their progress while providing real-time data to their healthcare team. Allurion Insights seamlessly integrates this data with the provider and facilitates end-to-end patient management by providing real-time patient analytics and telehealth features.
The new branding launched today includes new messaging, identity, logos, and other design elements that have been incorporated across all products to deliver a consistent and unified experience to patients and providers around the globe.
“The launch of our transformed Allurion Program and our new branding is the culmination of an initiative we began over a year ago to reimagine the future of weight loss and evolve from a company that offers a product to one that offers a revolutionary experience that delivers lifelong results,” said Shantanu Gaur, M.D., co-founder and CEO of Allurion Technologies. “We worked closely with our patients and providers to develop an experience that meets their needs, and we look forward to seeing the positive impact it will have on patient outcomes around the world.”
About Allurion Technologies
Allurion Technologies is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights. Learn more about Allurion online at www.allurion.com . Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release
The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release
Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and
Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release
Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom